After the fall in oil prices and the news of the identification of the new species Covid-19 Demand for safe haven increased. It remains to be seen how oil prices and new news about the new Covid-19 will go The most important support level is 127.988 If the price can not exceed this level, we can hope for a price increase.
Biotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical...
KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open...
UPI is ridiculously undervalued at $15M mkt cap and is a potential multi-bagger candidate from these levels. - Close to $10M in revenue in 2020 and is on pace to at least double it — recorded $1M in sales in the first week of June! - Profitable, no debt - Exclusive distributor of the 20-second non-invasive (finger scan) COVID-19 test that is currently undergoing...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19...
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish...
Why $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in...
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis. finance.yahoo.com
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine...
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific...
My last chart: November 22, 2020: Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA (The Motley Fool). Regeneron Covid Drug Gets Emergency OK. Antibody drug cocktail casirivimab and imdevimab are allowed for use by people over age 12 with mild or moderate Covid-19. (the street). If you are interested...
This pessimistic scenario is based upon current state of healthcare services in Poland which were underfinanced for many years and have very limited resources in qualified personell and equipment. There is significant lack of nurses and doctors in Poland not mentioning available hospital beds which means the system is near its breaking point. Recents countrywide...
VST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of...
I did a deep valuation analysis on Citigroup today, digging into their earnings reports for the last three years as well as analyst estimates for the next 4 quarters. Here are my conclusions. In forward P/S terms, Citigroup is nearly the cheapest it has been in the last three years. However, in forward P/E terms, it's nearly the most expensive it has been in the...
Hello traders, Australia has just moved Melbourne back into stage 3 lockdown for an additional 6 weeks. The AUD has performed extremely well over the past month due to the market pricing in an economic recovery. If other governments feel pressured to copy Victoria we could be set for a second lockdown in numerous parts of the world. This suggests the AUD may...
📍 The effect of Remdesivir... The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in. Compare the following two diagrams: Phase III trials & Chinese red carpet ...
XSPA began it's pilot covid-19 testing program this week in contract and in conjunction with JFK airport. More airports to follow and getting lots of media attention. XSPA was featured in a time magazine article today. I am long with an avg of $4.71. My price targets for the year are marked. I believe these will be hit by end of year. I will take profit at each...